Retatrutide Phase 3 Results: What Have Researchers Found?
- latitude40labs
- 1 day ago
- 5 min read
Retatrutide has moved beyond early-stage clinical research into a broad Phase 3 development program. Results reported in 2026 have increased scientific interest because multiple trials have reported substantial changes in body weight and other metabolic measures.
But Phase 3 results still need to be interpreted carefully. Some 2026 findings have been released as topline company results and are awaiting detailed peer-reviewed publication. Retatrutide also remains investigational and is not FDA-approved.
This article reviews the reported Phase 3 findings in plain language and separates what the studies show from questions that remain unanswered.
What Is the Phase 3 Program Studying?
Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the GIP, GLP-1 and glucagon receptors.
The Phase 3 program is much broader than the original obesity studies. Lilly reports that retatrutide is being studied across obesity, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic dysfunction-associated steatotic liver disease.
The purpose of Phase 3 is not simply to measure weight loss. These larger studies are designed to evaluate efficacy and safety in specific patient populations and clinical settings.
TRIUMPH-1: Retatrutide in Obesity
TRIUMPH-1 studied adults with obesity or overweight plus at least one weight-related condition who did not have diabetes.
In May 2026, Lilly reported that all three studied doses met the primary and key secondary endpoints at 80 weeks.
The reported average weight changes were:
4 mg: 19.0% reduction in body weight
9 mg: 24.2% reduction
12 mg: 28.3% reduction
Lilly also reported that 45.3% of participants receiving 12 mg achieved at least 30% weight reduction at 80 weeks.
These figures are averages for a clinical-trial population. They are not guarantees of individual results.
Longer-Term TRIUMPH-1 Findings
A study extension included participants with a baseline BMI of at least 35. Lilly reported that some participants continued to lose weight through 104 weeks, with the 12 mg group reaching an average reported reduction of 30.3%.
This longer follow-up is potentially important because it provides information beyond the original 80-week endpoint. However, longer-term research is still needed to understand the durability of treatment effects and the consequences of extended exposure.
TRIUMPH-2: Obesity and Type 2 Diabetes
TRIUMPH-2 evaluated adults with obesity or overweight and type 2 diabetes.
At 80 weeks, Lilly reported the following average body-weight reductions:
4 mg: 12.7%
9 mg: 19.1%
12 mg: 20.8%
Placebo: 4.0%
The study also reported improvements in A1C. Lilly reported average A1C reductions of 1.4%, 1.6% and 1.5% for the 4 mg, 9 mg and 12 mg groups, respectively, compared with 0.2% for placebo.
These results are particularly relevant because people with type 2 diabetes can respond differently to weight-management therapies than people without diabetes.
TRIUMPH-3: Severe Obesity and Cardiovascular Disease
TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.
At 80 weeks, Lilly reported average body-weight reductions of:
9 mg: 21.6%
12 mg: 22.6%
Placebo: 3.2%
The highest-dose group had an average reported reduction of 55.8 pounds.
The study also reported improvements in several cardiovascular risk factors, including triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference and high-sensitivity C-reactive protein.
What About Cardiovascular Events?
TRIUMPH-3 included analyses of major adverse cardiovascular events, or MACE.
Lilly reported that MACE events occurred less frequently than anticipated in both the retatrutide and placebo groups. The reported hazard ratio for MACE-5 was 0.82 with a 95% confidence interval of 0.55 to 1.22.
Because the confidence interval crossed 1.0, this result should not be interpreted as establishing a statistically significant cardiovascular benefit.
This distinction is important. Improvements in risk factors such as weight, blood pressure or lipids are not the same thing as proving that a treatment prevents cardiovascular events.
What Have Researchers Learned Across the Phase 3 Program?
The results reported so far provide several important observations.
Substantial weight reduction has been observed across multiple studied populations.
The reported weight changes generally increased with higher studied doses.
Retatrutide has also produced improvements in measures such as A1C in participants with type 2 diabetes.
Several Phase 3 studies are evaluating conditions beyond body weight.
The program is generating information about tolerability and safety across larger populations and longer follow-up periods.
Are the Phase 3 Results Final?
Not all of them are.
Some 2026 results discussed publicly are topline results released by Eli Lilly. Lilly has stated that detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals.
That means the initial announcements are useful for understanding the direction and scale of the findings, but the full peer-reviewed reports are important for evaluating study methods, statistical analyses, adverse events and subgroup results in detail.
What About Safety?
Safety remains one of the central questions in the Phase 3 program.
Earlier Phase 2 research identified gastrointestinal adverse events as common and observed dose-related increases in heart rate. Phase 3 studies provide substantially more exposure and follow-up, allowing researchers to collect additional safety information.
However, the complete long-term safety profile cannot be determined from a limited set of topline announcements. Larger datasets, longer follow-up and regulatory review remain important.
Does Phase 3 Mean Retatrutide Is Approved?
No. Phase 3 is an advanced stage of clinical development, but it is not the same as regulatory approval.
As of 2026, retatrutide remains investigational. Lilly has stated that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027.
Why These Results Matter
The significance of the Phase 3 program is that retatrutide is being studied in substantially broader and more diverse populations than in its earlier trials.
Researchers are no longer asking only whether the compound can reduce body weight. They are also studying how it performs in people with type 2 diabetes, cardiovascular disease and other obesity-related conditions, while collecting more information about safety and longer-term treatment.
What Researchers Still Don't Know
What the complete long-term safety profile will look like.
How retatrutide will compare directly with approved therapies in head-to-head clinical trials.
Whether changes in cardiovascular risk factors will translate into fewer cardiovascular events.
How durable the weight reduction will be over many years.
How regulators will evaluate the complete clinical-development package.
How results from clinical trials will translate to broader real-world populations.
The Bottom Line
The 2026 Phase 3 results have strengthened the clinical evidence surrounding retatrutide. Multiple trials have reported substantial average weight reductions, with additional improvements in measures such as A1C and several cardiovascular risk factors.
At the same time, these results should not be confused with FDA approval or with guaranteed individual outcomes. Some of the newest findings are topline company-reported data that still require detailed peer-reviewed publication.
The most accurate description of retatrutide today is an investigational triple-receptor agonist with a growing Phase 3 evidence base.
Continue Your Research
Sources & Further Reading
Educational Disclaimer
This article is provided for educational and research-information purposes only. It is not medical advice, diagnosis or treatment. Clinical-trial results describe study populations and should not be interpreted as guaranteed individual results. Retatrutide remains investigational and is not currently FDA-approved.
Explore the Research
Interested in exploring the compounds discussed in this article?
Visit Latitude 40 Aminos to explore our research-compound catalog and available product information.
Comments